News & Updates

Researchers from the University of Hong Kong (HKU) have developed a nanoparticle-based targeted drug delivery system that selectively transports thyroid hormone (TH) to adipose tissue, which may improve treatment of obesity and its related cardiometabolic complications by overcoming serious adverse events (AEs) associated with systematic TH administration.

Increased intake of omega-3 fatty acids is associated with lower all-cause mortality in individuals with diabetes, as reported in a study.

Further lowering blood pressure helps cut the risk of adverse perinatal events for pregnant women with pregestational diabetes mellitus (DM) and mild chronic hypertension, according to the secondary analysis of the Chronic Hypertension and Adverse Pregnancy (CHAP) study presented at SMFM 2023.

Using data from the ongoing population-based Tromsø study, baseline obesity was found to be associated with an increased risk of prefrailty/frailty in later years.

The use of sodium-glucose transporter 2 (SGLT2) inhibitors among patients with diabetes does not pose an increased risk of developing fractures as compared with dipeptidyl-peptidase 4 (DPP4) inhibitors, and this is true across estimated glomerular filtration rate (eGFR) and albuminuria categories, as shown in a study.

Paediatricians and other healthcare providers should treat childhood obesity immediately and at the highest level of intensity appropriate for and available to children, according to the new guideline published by the American Academy of Pediatrics (AAP).

Initiation of a glucagon-like peptide-1 (GLP-1) agonist at standard glycaemic control doses may result in modest weight loss through 72 weeks in patients with overweight or obesity and type 2 diabetes, suggest the results of a real-world study.